{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T04:01:55Z","timestamp":1789704115024,"version":"4.0.1"},"reference-count":33,"publisher":"SAGE Publications","issue":"6","license":[{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Lymphatic Research and Biology"],"published-print":{"date-parts":[[2018,12,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>This study examined interrelationships of selected interleukins (ILs), tumor growth factors, matrix metalloproteinases (MMPs), and C-reactive protein, interferon-gamma (IFN-\u03b3), and tumor necrosis factor \u03b1 (TNF-\u03b1) with lymphedema\/fibrosis in patients with head and neck cancer (HNC).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and Results:<\/jats:title>\n                    <jats:p>\n                      Patients newly diagnosed with \u2265Stage II HNC (\n                      <jats:italic toggle=\"yes\">N<\/jats:italic>\n                      \u2009=\u2009100) were assessed for external\/internal lymphedema and\/or fibrosis before treatment, end-of-treatment, and at regularly established intervals through 72 weeks posttreatment and blood was drawn. Data from 83 patients were analyzed. Group-based trajectory modeling generated patient groups with similar longitudinal biomarker and lymphedema\u2013fibrosis trajectories. Area-under-the-curve (AUC) values were also generated for each biomarker and severity of lymphedema\u2013fibrosis. Associations among and between biomarkers and lymphedema\u2013fibrosis trajectories and AUCs were tested (log-likelihood chi-square, correlations). The strongest evidence for the association of biomarkers with the overall and trajectory patterns and severity of lymphedema\u2013fibrosis was observed for IL-6, IL-1\u03b2, TNF-\u03b1, TGF-\u03b21, and MMP-9 (all\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009&lt;\u20090.05). Convergence of joint trajectory patterns and AUC were observed with IL-6 with all lymphedema\u2013fibrosis trajectories and internal lymphedema AUC. IL-1\u03b2 trajectories converged with external lymphedema trajectories and all lymphedema\u2013fibrosis AUCs. TNF-\u03b1 and TGF-\u03b21 converged most strongly with fibrosis in terms of trajectory patterns. However TNF-\u03b1 demonstrated stronger association with lymphedema\u2013fibrosis AUC (fibrosis:\n                      <jats:italic toggle=\"yes\">\n                        r\n                        <jats:sub>s<\/jats:sub>\n                      <\/jats:italic>\n                      \u2009=\u20090.49). MMP-9 demonstrated convergence with lymphedema\u2013fibrosis AUCs (lymphedema: 0.43\u20130.42; fibrosis: 0.35).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Systemic levels of selected mediators of proinflammatory processes track with acute and chronic clinical phenotypes of lymphedema\/fibrosis in HNC patients suggesting their potential role in the pathogenesis of these conditions.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1089\/lrb.2017.0074","type":"journal-article","created":{"date-parts":[[2018,11,28]],"date-time":"2018-11-28T11:24:48Z","timestamp":1543404288000},"page":"516-524","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":31,"title":["Biomarkers Associated with Lymphedema and Fibrosis in Patients with Cancer of the Head and Neck"],"prefix":"10.1177","volume":"16","author":[{"given":"Sheila H.","family":"Ridner","sequence":"first","affiliation":[{"name":"Vanderbilt University School of Nursing"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary S.","family":"Dietrich","sequence":"additional","affiliation":[{"name":"Vanderbilt University School of Nursing"},{"name":"Vanderbilt University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen T.","family":"Sonis","sequence":"additional","affiliation":[{"name":"Brigham and Women's Hospital and Dana-Farber Cancer Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Murphy","sequence":"additional","affiliation":[{"name":"Vanderbilt-Ingram Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2018,12,13]]},"reference":[{"key":"e_1_3_3_2_2","unstructured":"American Cancer Society. Facts and Figures 2017. 2017; Available at: https:\/\/www.cancer.org\/content\/dam\/cancer-org\/research\/cancer-facts-and-statistics\/annual-cancer-facts-and-figures\/2017\/cancer-facts-and-figures-2017.pdf. Accessed October17 2017."},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1586\/14737140.7.7.1043"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1097\/MOO.0b013e3283393799"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejon.2014.07.006"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1089\/lrb.2016.0001"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1159\/000078313"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1089\/jpm.2016.0018"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1089\/lrb.2016.29017.sr"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.0030254"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.03.00014703"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1152\/ajpheart.01019.2013"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.micinf.2006.05.003"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1089\/lrb.2010.0004"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1089\/lrb.2011.0008"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1089\/lrb.2011.0018"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00918794"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2007.08.037"},{"key":"e_1_3_3_19_2","volume-title":"Lymphedema: Understanding and Managing Lymphedema After Cancer Treatment","author":"American Cancer Society","year":"2006","unstructured":"American Cancer Society. Lymphedema: Understanding and Managing Lymphedema After Cancer Treatment. Atlanta, GA: American Cancer Society; 2006."},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1177\/000348940711600801"},{"key":"e_1_3_3_21_2","volume-title":"Cancer Therapy Evaluation Program","author":"National Cancer Institute","year":"2006","unstructured":"National Cancer Institute. Common Terminology Criteria for Adverse Events v3.0 (CTCAE). In: Cancer Therapy Evaluation Program. Washington, D.C.: National Institutes for Health; 2006."},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1189\/jlb.0802397"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1667\/RR3478.1"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10875-006-9022-6"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.62.suppl_2.ii43"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.1089\/lrb.2009.0022"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1000688"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.semradonc.2006.11.004"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.2307\/3579368"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.1002\/path.2277"},{"key":"e_1_3_3_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2008.02.046"},{"key":"e_1_3_3_32_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.179.9.6043"},{"key":"e_1_3_3_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.biocel.2007.08.016"},{"key":"e_1_3_3_34_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1300911"}],"container-title":["Lymphatic Research and Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/lrb.2017.0074","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/lrb.2017.0074","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/lrb.2017.0074","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T20:11:12Z","timestamp":1777666272000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1089\/lrb.2017.0074"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12,1]]},"references-count":33,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018,12,1]]}},"alternative-id":["10.1089\/lrb.2017.0074"],"URL":"https:\/\/doi.org\/10.1089\/lrb.2017.0074","relation":{},"ISSN":["1539-6851","1557-8585"],"issn-type":[{"value":"1539-6851","type":"print"},{"value":"1557-8585","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,12,1]]}}}